News

Article

Ruxolitinib Cream Could Provide Relief in Children Impacted by Atopic Dermatitis

The findings suggest that ruxolitinib cream could aid itch, pain, and sleep disturbance.

New findings from a phase 3 study that assessed ruxolitinib cream (Opzelura, Incyte) demonstrate that the cream could provide relief for atopic dermatitis (AD), a condition that impacts the quality of life among children. AD is a chronic, heterogenous, highly pruritic, relapsing inflammatory skin condition that impacts 10% of children.

Researchers conducted a randomized, double-blind, vehicle-controlled phase 3 study, named TRuE-AD3 (NCT04921969). The study included 330 children aged 2 to 11 years old with mild to moderate AD that persisted for longer than 3 months. The researchers aimed to evaluate patient/parent-reported outcomes (PROs) and sleep-related outcomes among children treated with ruxolitinib cream.

The researchers divided the children into 3 groups to either receive vehicle (N=65), 0.75% ruxolitinib cream (N=134) or 1.5% ruxolitinib cream (N=131) twice daily. The study extended for 8 weeks as the children participated in continuous treatment.

The study authors noted that baseline demographics, clinical characteristics, and baseline PROs were comparable among each treatment group (median [range] age, 6 [2–11] years; mean [SD] affected BSA, 10.5% [5.40%]; 76.4% of patients had a baseline Investigator’s Global Assessment [IGA] score of 3), according to study authors.

The results found at week 8 that adjusted mean improvements in patient-oriented eczema measure and itch numerical rating scale, total scores from baseline among the 1.5% ruxolitinib cream group, compared to vehicle were drastic. The total PRO score change was also significant from baseline to week 8. A greater than 6-point improvement from basline in PRO measured information system sleep disturbance or sleep-related impairment was also reported.

“More patients achieved a clinically important improvement (≥6-point) in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance or Sleep-Related Impairment from baseline with ruxolitinib cream than with vehicle,” said the study authors.

Futhermore, the PRO results displayed in children were consistent with phase 3 results among adolescents and adults.

The findings suggest that ruxolitinib cream could be a well-tolerated and effective treatment through week 8 among children aged 2 to 11, that experience mild to moderate AD— aiding itch, pain, and sleep disturbance.

Reference
Effect of Ruxolitinib Cream on Patient-Reported Outcomes (PROs) in Children Aged 2-<12 Years With Atopic Dermatitis (AD): Results From a Randomized, Double-Blind, Vehicle-Controlled Phase 3 Study (TRuE-AD3). Accessed March 8, 2024.
Related Videos
Healthcare, pharmacist and woman at counter with medicine or prescription drugs sales at drug store.
Image Credit: © Birdland - stock.adobe.com
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com